Skip to Content
Merck
  • Early salivary changes in multiple myeloma patients undergoing autologous HSCT.

Early salivary changes in multiple myeloma patients undergoing autologous HSCT.

Oral diseases (2018-04-11)
Sjm van Leeuwen, G B Proctor, Cmj Potting, S Ten Hoopen, Lfj van Groningen, E M Bronkhorst, Nma Blijlevens, McDnjm Huysmans
ABSTRACT

One explorative observational study in two parts was performed to examine early salivary changes in relation to oral mucositis (OM) in multiple myeloma patients treated with high-dose melphalan and autologous haematopoietic stem cell transplantation (HSCT). As cryotherapy was introduced after part A as regular care, its effect on OM could be evaluated. Unstimulated whole-mouth saliva (UWS) and stimulated whole-mouth saliva (SWS) were collected, and OM was scored with the Oral Mucositis Nursing Instrument (OMNI) at days -3, 0, 4, 7, 11 and 14 after HSCT. Salivary flow rate, total protein (BCA), mucin 5B, albumin (western blot), total IgA, lactoferrin and myeloperoxidase levels (ELISA) were determined. Trends of decreasing UWS and SWS flow rates and total IgA levels were observed. At days 7 and 11, increases in lactoferrin and albumin levels were found in UWS and SWS. A positive correlation was found between OMNI scores and albumin and lactoferrin levels in SWS (R2  = .56, p = .029 and R2  = .49, p = .043, respectively). In part B, cryotherapy significantly lowered peak OMNI scores. Compositional changes in saliva reflecting inflammation were found in the first days after HSCT, and the use of cryotherapy in the second part was associated with decreased OM severity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-Albumin antibody produced in mouse, clone HSA-11, ascites fluid